Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: Previous studies have shown Annexin A1 (AnxA1) and Annexin A2 (AnxA2) association with the aggressive behavior of Triple Negative Breast Cancer (TNBC). Our aim was to determine the correlation of AnxA1 and AnxA2 with poor prognosis of TNBC patients. Methods: We analyzed the gene expression of the human annexin family from microarray datasets and correlated with clinical outcomes to determine their ability to predict prognosis. Results: Within a mean follow-up time of 57.2 months in our TNBC cohort, high AnxA1 expression was an independent indicator of poor overall survival (OS) [hazard ratio (HR), 2.14; 95% confidence interval (CI), 1.22-3.78] and relapse-free survival (RFS) prognosis [HR, 1.66; 95% CI, 1.28-2.17]. Additionally, high AnxA2 expression was an independent indicator of poor OS [HR, 2.66; 95% CI, 1.14-6.25], RFS [HR, 1.45; 95% CI, 1.12-1.89], RFS [HR, 1.45; 95% CI, 1.12-1.89), and distant metastasis free survival (DMFS) prognosis [HR, 1.5; 95% CI, 1.16-1.95]. Analyses of TNBC patients with both high AnxA1 and AnxA2, demonstrates a significant decrease in OS (P=0.0017) and RFS (P=0.0002) when compared to the expression of genes independently. Furthermore, AnxA1 prognostic impact relies on high AnxA2 expression and both are preferential for TNBC when compared to other breast cancer subtypes. Conclusion: Together these findings indicate that AnxA1 and AnxA2 are preferential dual prognostic predictors among TNBC patients.

Original languageEnglish
Pages (from-to)2697-2704
Number of pages8
JournalOncotarget
Volume9
Issue number2
DOIs
StatePublished - 1 Jan 2018

Fingerprint

Annexin A2
Annexin A1
Triple Negative Breast Neoplasms
Gene Expression
Survival
Confidence Intervals
Annexins
Recurrence
Aptitude
Breast Neoplasms
Neoplasm Metastasis

Keywords

  • Annexin
  • Prognosis
  • Relapse
  • Survival
  • Triple-negative breast cancer

Cite this

@article{dbd7d29ed7ef4f8cac2d8838cdb469f9,
title = "Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer",
abstract = "Objective: Previous studies have shown Annexin A1 (AnxA1) and Annexin A2 (AnxA2) association with the aggressive behavior of Triple Negative Breast Cancer (TNBC). Our aim was to determine the correlation of AnxA1 and AnxA2 with poor prognosis of TNBC patients. Methods: We analyzed the gene expression of the human annexin family from microarray datasets and correlated with clinical outcomes to determine their ability to predict prognosis. Results: Within a mean follow-up time of 57.2 months in our TNBC cohort, high AnxA1 expression was an independent indicator of poor overall survival (OS) [hazard ratio (HR), 2.14; 95{\%} confidence interval (CI), 1.22-3.78] and relapse-free survival (RFS) prognosis [HR, 1.66; 95{\%} CI, 1.28-2.17]. Additionally, high AnxA2 expression was an independent indicator of poor OS [HR, 2.66; 95{\%} CI, 1.14-6.25], RFS [HR, 1.45; 95{\%} CI, 1.12-1.89], RFS [HR, 1.45; 95{\%} CI, 1.12-1.89), and distant metastasis free survival (DMFS) prognosis [HR, 1.5; 95{\%} CI, 1.16-1.95]. Analyses of TNBC patients with both high AnxA1 and AnxA2, demonstrates a significant decrease in OS (P=0.0017) and RFS (P=0.0002) when compared to the expression of genes independently. Furthermore, AnxA1 prognostic impact relies on high AnxA2 expression and both are preferential for TNBC when compared to other breast cancer subtypes. Conclusion: Together these findings indicate that AnxA1 and AnxA2 are preferential dual prognostic predictors among TNBC patients.",
keywords = "Annexin, Prognosis, Relapse, Survival, Triple-negative breast cancer",
author = "Gibbs, {Lee D.} and Vishwanatha, {Jamboor K.}",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.23627",
language = "English",
volume = "9",
pages = "2697--2704",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "2",

}

Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer. / Gibbs, Lee D.; Vishwanatha, Jamboor K.

In: Oncotarget, Vol. 9, No. 2, 01.01.2018, p. 2697-2704.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic impact of AnxA1 and AnxA2 gene expression in triple-negative breast cancer

AU - Gibbs, Lee D.

AU - Vishwanatha, Jamboor K.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: Previous studies have shown Annexin A1 (AnxA1) and Annexin A2 (AnxA2) association with the aggressive behavior of Triple Negative Breast Cancer (TNBC). Our aim was to determine the correlation of AnxA1 and AnxA2 with poor prognosis of TNBC patients. Methods: We analyzed the gene expression of the human annexin family from microarray datasets and correlated with clinical outcomes to determine their ability to predict prognosis. Results: Within a mean follow-up time of 57.2 months in our TNBC cohort, high AnxA1 expression was an independent indicator of poor overall survival (OS) [hazard ratio (HR), 2.14; 95% confidence interval (CI), 1.22-3.78] and relapse-free survival (RFS) prognosis [HR, 1.66; 95% CI, 1.28-2.17]. Additionally, high AnxA2 expression was an independent indicator of poor OS [HR, 2.66; 95% CI, 1.14-6.25], RFS [HR, 1.45; 95% CI, 1.12-1.89], RFS [HR, 1.45; 95% CI, 1.12-1.89), and distant metastasis free survival (DMFS) prognosis [HR, 1.5; 95% CI, 1.16-1.95]. Analyses of TNBC patients with both high AnxA1 and AnxA2, demonstrates a significant decrease in OS (P=0.0017) and RFS (P=0.0002) when compared to the expression of genes independently. Furthermore, AnxA1 prognostic impact relies on high AnxA2 expression and both are preferential for TNBC when compared to other breast cancer subtypes. Conclusion: Together these findings indicate that AnxA1 and AnxA2 are preferential dual prognostic predictors among TNBC patients.

AB - Objective: Previous studies have shown Annexin A1 (AnxA1) and Annexin A2 (AnxA2) association with the aggressive behavior of Triple Negative Breast Cancer (TNBC). Our aim was to determine the correlation of AnxA1 and AnxA2 with poor prognosis of TNBC patients. Methods: We analyzed the gene expression of the human annexin family from microarray datasets and correlated with clinical outcomes to determine their ability to predict prognosis. Results: Within a mean follow-up time of 57.2 months in our TNBC cohort, high AnxA1 expression was an independent indicator of poor overall survival (OS) [hazard ratio (HR), 2.14; 95% confidence interval (CI), 1.22-3.78] and relapse-free survival (RFS) prognosis [HR, 1.66; 95% CI, 1.28-2.17]. Additionally, high AnxA2 expression was an independent indicator of poor OS [HR, 2.66; 95% CI, 1.14-6.25], RFS [HR, 1.45; 95% CI, 1.12-1.89], RFS [HR, 1.45; 95% CI, 1.12-1.89), and distant metastasis free survival (DMFS) prognosis [HR, 1.5; 95% CI, 1.16-1.95]. Analyses of TNBC patients with both high AnxA1 and AnxA2, demonstrates a significant decrease in OS (P=0.0017) and RFS (P=0.0002) when compared to the expression of genes independently. Furthermore, AnxA1 prognostic impact relies on high AnxA2 expression and both are preferential for TNBC when compared to other breast cancer subtypes. Conclusion: Together these findings indicate that AnxA1 and AnxA2 are preferential dual prognostic predictors among TNBC patients.

KW - Annexin

KW - Prognosis

KW - Relapse

KW - Survival

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85039996292&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.23627

DO - 10.18632/oncotarget.23627

M3 - Article

AN - SCOPUS:85039996292

VL - 9

SP - 2697

EP - 2704

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 2

ER -